文献速递精神分裂症与精神病性障碍

精神分裂症患者外周血白细胞亚群差异:系统综述与Meta分析

Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该系统综述与Meta分析纳入64篇文章(60项横断面/病例对照研究和4项纵向研究),比较精神分裂症患者与健康对照的外周血白细胞亚群计数。结果显示患者中性粒细胞(g=0.69)和单核细胞(g=0.49)升高,且首发未治疗者差异更大;嗜酸性粒细胞、嗜碱性粒细胞和淋巴细胞无显著差异。成功治疗急性精神病后中性粒细胞纵向下降(g=-0.30),嗜酸性粒细胞纵向升高(g=0.61)。

要点

  • 精神分裂症患者中性粒细胞(g=0.69)和单核细胞(g=0.49)较健康对照升高。
  • 中性粒细胞和单核细胞升高在首发患者及未治疗患者中更明显。
  • 成功治疗急性精神病后中性粒细胞纵向下降,嗜酸性粒细胞纵向升高。

核心结论

  • 精神分裂症患者血中性粒细胞和单核细胞升高支持免疫假说,尤其提示先天免疫激活的作用。
  • 这些效应在疾病早期更明显并反映临床改善,可能为基于免疫和炎症通路的创新治疗策略开辟道路。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Web of Science、Scopus和Cochrane Library数据库,末次检索为2024年1月。
  • 纳入比较精神分裂症患者与健康对照白细胞计数的横断面、病例对照和纵向研究,去重后筛选3691项研究。
  • 最终纳入64篇文章(60项横断面/病例对照研究和4项纵向研究),包含26349例精神分裂症患者和16379名健康对照的白细胞数据。
  • 数据由2名作者独立提取,遵循PRISMA和MOOSE指南,采用随机效应模型合并。

主要发现

  • 中性粒细胞在精神分裂症患者中高于对照(g=0.69;95%CI 0.49至0.89;Bonferroni校正P<.001;n=40951[47项组间比较])。
  • 单核细胞在精神分裂症患者中高于对照(g=0.49;95%CI 0.24至0.75;Bonferroni校正P<.001;n=40513[44项组间比较])。
  • 中性粒细胞和单核细胞的差异在首发vs慢性精神分裂症以及未治疗vs抗精神病药治疗患者中更大。
  • 嗜酸性粒细胞(g=0.02;95%CI -0.16至0.20;Bonferroni校正P>.99;n=3277[18项组间比较])、嗜碱性粒细胞(g=0.14;95%CI -0.06至0.34;Bonferroni校正P=.85;n=2614[13项组间比较])和淋巴细胞(g=-0.08;95%CI -0.21至0.06;Bonferroni校正P>.99;n=41693[59项组间比较])无显著差异。
  • 成功治疗急性精神病后,中性粒细胞纵向下降(g=-0.30;95%CI -0.45至-0.15;Bonferroni校正P<.001;n=896[4项组内比较]),嗜酸性粒细胞纵向升高(g=0.61;95%CI 0.52至0.71;Bonferroni校正P<.001;n=876[3项组内比较])。

关键数值与推荐

  • 中性粒细胞升高:g=0.69(95%CI 0.49至0.89),Bonferroni校正P<.001,n=40951,47项组间比较。
  • 单核细胞升高:g=0.49(95%CI 0.24至0.75),Bonferroni校正P<.001,n=40513,44项组间比较。
  • 嗜酸性粒细胞无显著差异:g=0.02(95%CI -0.16至0.20),Bonferroni校正P>.99,n=3277,18项组间比较。
  • 嗜碱性粒细胞无显著差异:g=0.14(95%CI -0.06至0.34),Bonferroni校正P=.85,n=2614,13项组间比较。
  • 淋巴细胞无显著差异:g=-0.08(95%CI -0.21至0.06),Bonferroni校正P>.99,n=41693,59项组间比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: This study aims to provide robust evidence to support or challenge the immune hypothesis of schizophrenia. OBJECTIVE: To conduct a meta-analysis of reports on blood leukocyte subpopulations in schizophrenia vs healthy controls, examining disease- and treatment-related differences as well as potential confounders. DATA SOURCES: Systematic database search for English and non-English peer-reviewed articles in PubMed, Web of Science, Scopus, and Cochrane Library databases, with the last search in January 2024. STUDY SELECTION: Cross-sectional, case-control, and longitudinal studies comparing leukocyte numbers in patients with schizophrenia and healthy controls. After duplicates were removed, 3691 studies were identified for screening. DATA EXTRACTION AND SYNTHESIS: Data extraction and quality assessment were conducted following PRISMA and MOOSE guidelines. Data were independently extracted by 2 authors and pooled using random-effects models. MAIN OUTCOMES AND MEASURES: The planned primary outcomes were differences in leukocyte subpopulation counts between individuals with schizophrenia and healthy controls to increase our understanding of the immune system dysfunction in schizophrenia. RESULTS: Sixty-four relevant articles were identified (60 cross-sectional/case-control studies and 4 longitudinal studies) with data on leukocyte numbers from 26 349 individuals with schizophrenia and 16 379 healthy controls. Neutrophils (g = 0.69; 95% CI, 0.49 to 0.89; Bonferroni-adjusted P < .001; n = 40 951 [47 between-group comparisons]) and monocytes (g = 0.49; 95% CI, 0.24 to 0.75; Bonferroni-adjusted P < .001; n = 40 513 [44 between-group comparisons]) were higher in schizophrenia compared with control participants. Differences were greater in first-episode vs chronic schizophrenia and in patients who were not treated vs treated with antipsychotic medication. There were no significant differences in eosinophils (g = 0.02; 95% CI, -0.16 to 0.20; Bonferroni-adjusted P > .99; n = 3277 [18 between-group comparisons]), basophils (g = 0.14; 95% CI, -0.06 to 0.34; Bonferroni-adjusted P = .85; n = 2614 [13 between-group comparisons]), or lymphocytes (g = -0.08; 95% CI, -0.21 to 0.06; Bonferroni-adjusted P > .99; n = 41 693 [59 between-group comparisons]). Neutrophils decreased longitudinally (g = -0.30; 95% CI, -0.45 to -0.15; Bonferroni-adjusted P < .001; n = 896 [4 within-group comparisons]) and eosinophils increased longitudinally (g = 0.61; 95% CI, 0.52 to 0.71; Bonferroni-adjusted P < .001; n = 876 [3 within-group comparisons]) after successful treatment of acute psychosis. CONCLUSIONS AND RELEVANCE: Our findings of increased blood neutrophils and monocytes support the immune hypothesis of schizophrenia, particularly highlighting the role of innate immune activation. As these effects were more pronounced in early disease stages and also reflected clinical improvement, they may pave the way for innovative treatment strategies based on immunological and inflammatory pathways and help revolutionize the treatment landscape for schizophrenia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dudeck L, Nussbaumer M, Nickl-Jockschat T, et al. Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40042836. doi:10.1001/jamapsychiatry.2024.4941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。